Annual Cash & Cash Equivalents
$30.62 M
-$288.00 K-0.93%
December 31, 2023
Summary
- As of March 6, 2025, VYNE annual cash & cash equivalents is $30.62 million, with the most recent change of -$288.00 thousand (-0.93%) on December 31, 2023.
- During the last 3 years, VYNE annual cash & cash equivalents has fallen by -$26.94 million (-46.81%).
- VYNE annual cash & cash equivalents is now -46.81% below its all-time high of $57.56 million, reached on December 31, 2020.
Performance
VYNE Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$16.27 M
-$13.34 M-45.04%
September 30, 2024
Summary
- As of March 6, 2025, VYNE quarterly cash and cash equivalents is $16.27 million, with the most recent change of -$13.34 million (-45.04%) on September 30, 2024.
- Over the past year, VYNE quarterly cash and cash equivalents has stayed the same.
- VYNE quarterly cash and cash equivalents is now -86.27% below its all-time high of $118.52 million, reached on March 31, 2021.
Performance
VYNE Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
VYNE Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -0.9% | 0.0% |
| 3 y3 years | -46.8% | -47.4% |
| 5 y5 years | -38.1% | -47.4% |
VYNE Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -27.5% | at low | -67.8% | +5.3% |
| 5 y | 5-year | -46.8% | at low | -86.3% | +5.3% |
| alltime | all time | -46.8% | +660.4% | -86.3% | +304.1% |
VYNE Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $16.27 M(-45.0%) |
| Jun 2024 | - | $29.61 M(+55.3%) |
| Mar 2024 | - | $19.07 M(-37.7%) |
| Dec 2023 | $30.62 M(-0.9%) | $30.62 M(+98.2%) |
| Sep 2023 | - | $15.45 M(-25.1%) |
| Jun 2023 | - | $20.63 M(-31.7%) |
| Mar 2023 | - | $30.21 M(-2.2%) |
| Dec 2022 | $30.91 M(-26.8%) | $30.91 M(-13.0%) |
| Sep 2022 | - | $35.51 M(-17.1%) |
| Jun 2022 | - | $42.81 M(-15.2%) |
| Mar 2022 | - | $50.49 M(+19.5%) |
| Dec 2021 | $42.25 M(-26.6%) | $42.25 M(-19.2%) |
| Sep 2021 | - | $52.31 M(-49.4%) |
| Jun 2021 | - | $103.41 M(-12.7%) |
| Mar 2021 | - | $118.52 M(+105.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2020 | $57.56 M(+87.0%) | $57.56 M(-21.1%) |
| Sep 2020 | - | $72.96 M(-24.4%) |
| Jun 2020 | - | $96.51 M(+67.6%) |
| Mar 2020 | - | $57.60 M(+87.2%) |
| Dec 2019 | $30.78 M(-37.8%) | $30.78 M(-10.1%) |
| Sep 2019 | - | $34.24 M(-47.4%) |
| Jun 2019 | - | $65.06 M(+5.0%) |
| Mar 2019 | - | $61.96 M(+25.1%) |
| Dec 2018 | $49.51 M(+385.1%) | $49.51 M(-29.5%) |
| Sep 2018 | - | $70.20 M(-4.6%) |
| Jun 2018 | - | $73.58 M(-6.3%) |
| Mar 2018 | - | $78.53 M(+669.4%) |
| Dec 2017 | $10.21 M(+153.4%) | $10.21 M(-31.8%) |
| Sep 2017 | - | $14.96 M(+271.4%) |
| Dec 2016 | $4.03 M(-90.8%) | $4.03 M |
| Dec 2015 | $43.81 M | - |
FAQ
- What is VYNE Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for VYNE Therapeutics?
- What is VYNE Therapeutics annual cash & cash equivalents year-on-year change?
- What is VYNE Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for VYNE Therapeutics?
- What is VYNE Therapeutics quarterly cash and cash equivalents year-on-year change?
What is VYNE Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of VYNE is $30.62 M
What is the all time high annual cash & cash equivalents for VYNE Therapeutics?
VYNE Therapeutics all-time high annual cash & cash equivalents is $57.56 M
What is VYNE Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, VYNE annual cash & cash equivalents has changed by -$288.00 K (-0.93%)
What is VYNE Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of VYNE is $16.27 M
What is the all time high quarterly cash and cash equivalents for VYNE Therapeutics?
VYNE Therapeutics all-time high quarterly cash and cash equivalents is $118.52 M
What is VYNE Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, VYNE quarterly cash and cash equivalents has changed by $0.00 (0.00%)